Highlights
- Andy Goodwin, Chief Technology Officer of First Graphene Ltd, to present at international conference.
- New data supporting the high quality of PureGRAPH™ graphenes will be presented.
- The benefits of using PureGRAPH™ in key vertical markets will be summarised.
Advanced materials company, First Graphene Limited (“FGR” or “the Company”) (ASX: FGR) is pleased to announce Chief Technology Officer, Dr Andy Goodwin will present at the Graphene Automotive 2019 conference and exhibition in Detroit on 4th and 5th March 2019. Andy has also been invited to chair Day 1 of the conference.
First Graphene Ltd. will provide an update on the measures that have been implemented to ensure the batch to batch quality of PureGRAPH™ products manufactured at Henderson, WA. The Company will also present the latest information on the fundamental properties of PureGRAPH™ products underlining these are righty called graphene materials. The presentation will also contain an update of our progress in key applications.
The new fundamental data indicates PureGRAPH™ is a low-defect, high aspect ratio graphene product with low metal and silicon contaminations levels. PureGRAPH™ has been shown by microscopy to contain high levels of Few Layer Graphene platelets. Raman analysis indicates the average platelet thickness is < 10 layers.
One of the impediments to a more rapid commercialisation of graphene has been the inconsistency of quality material available for purchase. While many organisations state they can produce graphene the buyers have had issues with quality. Recognising this issue, FGR has gone to considerable lengths to ensure a high-quality product fit for delivery to industry.
“We continue to implement testing and monitoring tools that ensure the quality of PureGRAPH™ products for our customers” said Craig McGuckin, Managing Director First Graphene Ltd. “we will also continue to publish the more fundamental information on our products as this information becomes available from our ongoing collaborations with leading universities”.
A copy of Dr Goodwin’s presentation will be made available on the Company’s’ website.